Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children
M Knuf, G Leroux-Roels, H Rümke… - Human vaccines & …, 2015 - Taylor & Francis
Mass immunization of children has the potential to decrease infection rates and prevent the
transmission of influenza. We evaluated the immunogenicity, safety, and tolerability of …
transmission of influenza. We evaluated the immunogenicity, safety, and tolerability of …
Safety and immunogenicity of an MF59®-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age
M Knuf, G Leroux-Roels, HC Rümke, K Abarca… - Vaccine, 2015 - Elsevier
Objectives This study was designed to identify the optimal dose of an MF59®-adjuvanted,
monovalent, A/H1N1 influenza vaccine in healthy paediatric subjects. Methods Subjects …
monovalent, A/H1N1 influenza vaccine in healthy paediatric subjects. Methods Subjects …
Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6–35 months of age
M Knuf, G Leroux-Roels, HC Rümke… - The Pediatric …, 2014 - journals.lww.com
Background: Vaccines against pandemic A/H1N1 influenza should provide protective
immunity in children, because they are at greater risk of disease than adults. This study was …
immunity in children, because they are at greater risk of disease than adults. This study was …
Homologous and heterologous antibody responses to a one-year booster dose of an MF59®: Adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric …
T Vesikari, A Forstén, A Borkowski… - Human vaccines & …, 2012 - Taylor & Francis
Background: Primary immunization with two doses of MF59®-adjuvanted A/H5N1 influenza
vaccine has been shown to be highly immunogenic and well tolerated in children and …
vaccine has been shown to be highly immunogenic and well tolerated in children and …
MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination
T Vesikari, N Groth, A Karvonen, A Borkowski… - Vaccine, 2009 - Elsevier
After priming with two intramuscular doses of MF59®-adjuvanted (Sub/MF59) or split
influenza vaccines during the 2006/07 season, 89 healthy children received a third booster …
influenza vaccines during the 2006/07 season, 89 healthy children received a third booster …
Safety, tolerability and immunogenicity of an mf59-adjuvanted, cell culture-derived, a/h5n1, subunit influenza virus vaccine: Results from a dose-finding clinical trial in …
P Chanthavanich, E Anderson… - The Pediatric …, 2019 - journals.lww.com
Background: A/H5N1 influenza virus has significant pandemic potential, and vaccination is
the main prophylactic measure. This phase 2, randomized, observer-blind, multicenter study …
the main prophylactic measure. This phase 2, randomized, observer-blind, multicenter study …
Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence
T Vesikari, A Karvonen, S Tilman, A Borkowski… - …, 2010 - publications.aap.org
OBJECTIVE: This study evaluated the immunogenicity, safety, and tolerability of a MF59-
adjuvanted H5N1 vaccine in a population 6 months through 17 years of age. METHODS …
adjuvanted H5N1 vaccine in a population 6 months through 17 years of age. METHODS …
Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children
Y Yasuda, R Komatsu, K Matsushita, T Minami… - Advances in …, 2010 - Springer
Introduction The substantial pandemic (A/H1N1v) influenza disease burden in children
highlights the need for effective vaccination. We report the results of modern cell culture …
highlights the need for effective vaccination. We report the results of modern cell culture …
Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza …
G Palladino, A Ferrari, N Music, EC Settembre, Y Wen - Vaccine, 2021 - Elsevier
Vaccination is the most effective approach to reduce the substantial morbidity and mortality
caused by influenza infection. Vaccine efficacy is highly sensitive to antigenic changes …
caused by influenza infection. Vaccine efficacy is highly sensitive to antigenic changes …
Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six-to less than thirty-six-month-old children
SL Block, GM Ruiz-Palacios, ML Guerrero… - The Pediatric …, 2012 - journals.lww.com
Background: The successful vaccination of children 6 to 36 months of age against 2009
A/H1N1 influenza was essential to help reduce the burden of pandemic disease in both the …
A/H1N1 influenza was essential to help reduce the burden of pandemic disease in both the …